>Press Releases

Yuhan signs $1.25 billion licensing deal with Janssen

Lasertinib(GNS-1480), discovered by Genosco, was out-licensed to Janssen.

By | November 6th, 2018|

Early results from a 3rd gen EGFR-TKI in advanced NSCLC

Dr. Cho speaks with ecancer at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting about a phase I/II trial of lazertinib(GNS-1480, YH25448), a highly selective and irreversible investigational 3rd-generation EGFR-TKI.

By | June 3rd, 2018|

ASCO 2018: Genosco/Yuhan Announce Results from Phase 1/2 Study of Lazertinib (YH25448, GNS-1480), a 3rd-Generation EGFR-TKI, in Advanced NSCLC

By | June 3rd, 2018|

Genosco/Yuhan Announce Results from Phase 1/2 Study of YH25448(GNS-1480), a 3rd-Generation EGFR-TKI, in Advanced NSCLC to be Presented at ASCO 2018

Business Wire * May 16, 2018; Abstract - https://meetinglibrary.asco.org/record/161036/abstract

By | May 16th, 2018|
Load More Posts